Last updated on

Journal of Clinical Oncology
Research Hotspot & Journal Scope - NSCLC


Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.8503
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

David J. Kwiatkowski · Valerie W. Rusch · Jamie E. Chaft · Bruce E. Johnson · Alan Nicholas · Ignacio Ivan Wistuba · Robert E. Merritt · Jay M. Lee · Paul A. Bunn · Yan Tang · See-Chun Phan · Saiama N. Waqar · Alexander Patterson · Eric B. Haura · Eric M. Toloza · Karen L. Reckamp · Dan J. Raz · Katja Schulze · Ann M. Johnson · David P. Carbone ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.9000
RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Kazuhiko Nakagawa · Edward B. Garon · Takashi Seto · Makoto Nishio · Santiago Ponce Aix · Chao-Hua Chiu · Keunchil Park · Silvia Novello · Ernest Nadal · Fumio Imamura · Kiyotaka Yoh · Jin-Yuan Shih · Kwok Hung Au · Denis Moro-Sibilot · Sotaro Enatsu · Annamaria Zimmermann · Bente Frimodt-Moller · Carla M. Visseren Grul · Martin Reck ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.9017
Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).

Lingzhi Hong · Seyedeh Dibaj · Marcelo Vailati Negrao · Alexandre Reuben · Emily Roarty · Waree Rinsurongkawong · Jeffrey A. Lewis · Don Lynn Gibbons · Boris Sepesi · Vassiliki A Papadimitrakopoulou · Bonnie S. Glisson · George R. Blumenschein · Phillip Andrew Futreal · Ignacio Ivan Wistuba · Jack A. Roth · Stephen G. Swisher · John Victor Heymach · George R. Simon · Jiun-Kae Jack Lee · Jianjun Zhang ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.8502
Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) +/- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC).

Theodoros Tsakiridis · Chen Hu · Heath D. Skinner · Rafael Santana-Davila · Bo Lu · Jeremy J. Erasmus · A Doemer · Gregory M.M. Videtic · J. Coster · Xuezhong Yang · Richard J. Lee · Maria Werner-Wasik · Philip E. Schaner · Steven Eric McCormack · Benjamin T. Esparaz · Ronald C. McGarry · Jose G. Bazan · Timothy Struve · Jeffrey D. Bradley ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/jco.2019.37.27_suppl.3
Effect of high patient out-of-pocket (OOP) cost for oral tyrosine kinase inhibitors (TKIs) on survival in EGFR and ALK positive stage IV non-small cell lung cancer (NSCLC).

Bernardo H. L. Goulart · Joseph M. Unger · Shasank Chennupati · Kathryn Egan · Catherine R. Fedorenko · Scott D. Ramsey ·

Medicine
PDF

CANOPY-1 (NCT03631199) is a placebo-controlled, double-blind, randomized, phase 3 trial designed to evaluate efficacy and safety of PEM + Ctx ± CAN in previously untreated pts with stage IIIB/IIIC (not eligible for definitive chemo-radiation curative tx) or stage IV squamous and nonsquamous NSCLC.

Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1) [10.1158/1535-7163.TARG-19-C100]


The appropriate management of adverse events and dose reduction of afatinib are important for EGFR‐positive NSCLC patients.

Clinical analysis of EGFR‐positive non‐small cell lung cancer patients treated with first‐line afatinib: A Nagano Lung Cancer Research Group [10.1111/1759-7714.13047]


The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic NSCLC cancer in Asian patients.

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS [10.1093/annonc/mdy554]


49) was an indicator of poor survival, especially in advanced-stage NSCLC patients.

Circular RNA circHIPK3 modulates autophagy via MIR124-3p-STAT3-PRKAA/AMPKα signaling in STK11 mutant lung cancer [10.1080/15548627.2019.1634945]


Die Checkpointinhibition hält auch Einzug in die Therapie des NSCLC — mit entsprechenden Implikationen.

Stellenwert der Immuntherapie [10.1007/s15004-019-6779-3]



Research Hotspot

Journal of Clinical Oncology

Research Hotspot
Journal of Clinical Oncology Related Journals

Popular Journals